Abstract
Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Current Pharmaceutical Biotechnology
Title:Brain Drug Delivery Systems for Neurodegenerative Disorders
Volume: 13 Issue: 12
Author(s): E. Garbayo, E. Ansorena and M.J. Blanco-Prieto
Affiliation:
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Abstract: Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Export Options
About this article
Cite this article as:
Garbayo E., Ansorena E. and Blanco-Prieto M.J., Brain Drug Delivery Systems for Neurodegenerative Disorders, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341761
DOI https://dx.doi.org/10.2174/138920112803341761 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Nanotechnology Driven Approaches for the Management of Parkinson’s Disease: Current Status and Future Perspectives
Current Drug Metabolism Proteomics and Neurodegenerative Disorders: Advancements in the Diagnostic Analysis
Current Protein & Peptide Science Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry The Potential Dual Effects of Anesthetic Isoflurane on Aβ-Induced Apoptosis
Current Alzheimer Research Pomegranate as a Possible Treatment in Reducing Risk of Developing Wound Healing, Obesity, Neurodegenerative Disorders, and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Synthesis of Novel 4-(Dimethylaminoalkyl)piperazine-1-carbodithioa t e Derivatives as Cholinesterase Inhibitors
Letters in Drug Design & Discovery The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase
Central Nervous System Agents in Medicinal Chemistry Recent Approaches Targeting Beta-Amyloid for Therapeutic Intervention of Alzheimer's disease
Recent Patents on CNS Drug Discovery (Discontinued) Resveratrol Protects β Amyloid-Induced Oxidative Damage and Memory Associated Proteins in H19-7 Hippocampal Neuronal Cells
Current Alzheimer Research Phytochemicals Targeting Oxidative Stress, Interconnected Neuroinflammatory, and Neuroapoptotic Pathways Following Radiation
Current Neuropharmacology Protein Misfolding Diseases and Therapeutic Approaches
Current Protein & Peptide Science In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Role of Autophagy in Parkinson’s Disease
Current Medicinal Chemistry Molecule of the Month
Current Topics in Medicinal Chemistry Genetics and Bioenergetics of Mitochondria Influencing the Etiology and Pharmacology of Steroidal Hormones
Current Pharmacogenomics